Immune Checkpoint Inhibitor–Related Myositis, Myocarditis, and Myasthenia Gravis Overlap Syndrome:

Background and clinical importance of the overlap syndrome

The article title identifies a systematic review and pooled analysis addressing overlap syndrome involving immune checkpoint inhibitors (ICIs) and the neuromuscular and cardiac conditions myositis, myocarditis, and myasthenia gravis (MG). These immune-related adverse events are recognized complications of checkpoint blockade and may present concurrently or sequentially, producing substantial morbidity and potential mortality when cardiac or respiratory muscles are affected. Overlap presentations are clinically important because combined involvement can complicate diagnosis, accelerate clinical deterioration, and influence therapeutic decisions.

Available source content and key missing article elements

The publicly accessible content from the provided Frontiers in Immunology URL includes site navigation, journal information, and links but does not include the manuscript text, abstract, methods, results, or authors’ conclusions. As a result, the following critical study elements are not reported in the source and therefore cannot be summarized here:

• Inclusion and exclusion criteria used for the systematic review.
• The search strategy, databases searched, and date range covered.
• Number of individual cases identified and pooled for analysis.
• Patient demographics (age, sex, cancer type).
• Specific ICIs implicated (e.g., anti–PD-1, anti–PD-L1, anti–CTLA-4) and whether monotherapy or combination therapy predominated.
• Temporal patterns such as median time from ICI initiation to symptom onset.
• Diagnostic tests used (e.g., troponin, CK, EMG, anti–acetylcholine receptor antibodies, cardiac MRI, endomyocardial or muscle biopsy) and their reported frequencies.
• Management strategies applied (e.g., corticosteroids, IVIG, plasmapheresis, immunosuppressants) and timing of interventions.
• Clinical outcomes including recovery rates, persistent deficits, respiratory failure, arrhythmia, need for mechanical ventilation, or deaths.
• Pooled quantitative results, heterogeneity measures, and risk-of-bias assessments.

Because these items are absent from the retrieved source content, no numerical findings, pooled estimates, or study-level conclusions can be asserted here without risking fabrication.

Implications for clinicians prescribing immune checkpoint inhibitors

Although the original article content is not available in the provided source, the topic signaled by the title has clear clinical relevance. Clinicians should remain vigilant for signs of neuromuscular and cardiac toxicity in patients receiving ICIs. Overlap presentations may include proximal weakness, bulbar symptoms, fluctuating fatigability suggestive of myasthenia gravis, elevated muscle enzymes consistent with myositis, and chest pain, dyspnea, or conduction abnormalities indicating myocarditis. Rapid recognition is crucial because cardiac involvement may be life-threatening.

However, because the source text does not provide specific case numbers, diagnostic algorithms, or recommended management timelines, clinicians should rely on established guidelines, institutional protocols, and the complete peer-reviewed article once obtained for evidence-based, case-specific decision-making.

Typical diagnostic considerations for myositis, myocarditis, and myasthenia gravis overlap (not reported in source)

The source does not report the diagnostic criteria or testing approaches used in the review. In clinical practice, evaluation of a suspected overlap includes:

• Laboratory testing: creatine kinase (CK), troponin, inflammatory markers, and autoimmune serologies when indicated.
• Neurophysiology: repetitive nerve stimulation or single-fiber EMG for MG; EMG for myositis.
• Cardiac imaging: echocardiography and cardiac MRI to detect myocarditis; ECG monitoring for arrhythmias.
• Autoantibody testing: anti–acetylcholine receptor and other MG-associated antibodies when clinically indicated.
• Tissue biopsy: endomyocardial or skeletal muscle biopsy may be definitive but are invasive and used selectively.

Because the review details are not present, it is not possible here to report which diagnostic approaches were most commonly applied, how frequently they confirmed pathology, or how they correlated with outcomes in the pooled cases.

Management principles commonly applied in checkpoint inhibitor–related neuromuscular and cardiac toxicity (not reported in source)

The article text that would describe therapies used and their outcomes is not included on the accessible page. Generally, management of severe ICI-related myositis, myocarditis, or MG overlap follows these principles:

• Immediate hold or permanent discontinuation of the offending ICI depending on severity.
• Early and often high-dose corticosteroids as first-line immunosuppression for moderate to severe presentations.
• Consideration of adjunctive therapies such as intravenous immunoglobulin (IVIG), plasmapheresis, or additional immunosuppressive agents for steroid-refractory disease or severe neuromuscular respiratory compromise.
• Supportive measures including cardiology involvement, intensive monitoring, and respiratory support when needed.

The present source does not supply aggregated data on the effectiveness, timing, or adverse effects of these interventions in the reviewed cases.

Knowledge gaps and recommended next steps to obtain the full data

Because the manuscript body and pooled-case analyses are not present in the provided source content, key knowledge gaps remain that must be resolved before applying conclusions clinically. Recommended steps:

• Access the full article via the Frontiers in Immunology site, institutional library, or the DOI to review the complete methods, case counts, and pooled outcomes.
• Review supplementary materials and any case-level tables to understand diagnostic definitions and treatment algorithms used by the authors.
• Evaluate the authors’ risk-of-bias assessment and heterogeneity metrics to judge the reliability of pooled analyses.
• If necessary, contact the corresponding author or publisher for clarifications or raw case data if the published supplement is incomplete.

Conclusion and limitations due to missing source text

The available page identifies an important systematic review topic—overlap syndrome of myositis, myocarditis, and myasthenia gravis associated with immune checkpoint inhibitors—but does not include the manuscript content needed to summarize findings. No case counts, pooled results, or authors’ recommendations are extractable from the provided content. Any clinical interpretation or application requires direct review of the full, peer-reviewed article. Until the complete text and data are obtained, clinicians should rely on established practice guidelines and multidisciplinary consultation when managing suspected ICI-related overlap syndromes.

Source limitation statement: the source content supplied for this rewrite consisted only of journal navigation and metadata; the article abstract, methods, results, and conclusions were not available for extraction. All specific study details requested by readers were therefore reported as not reported in the source.